UroAlerts - Prostate Cancer Weekly

Prostate Cancer

Prostate cancer incidence and mortality in Europe and implications for screening activities: population based study.

Cancer cell states: Lessons from ten years of single-cell RNA-sequencing of human tumors

Germline Pathogenic Variants Identified in Patients With Genitourinary Malignancies Undergoing Universal Testing: A Multisite Single-Institution Prospective Study

Adiposity and Muscle Strength in Men With Prostate Cancer and Cardiovascular Outcomes

Intra-prostatic recurrences after radiotherapy with focal boost: Location and dose mapping in the FLAME trial.

Prognostic factors in post-prostatectomy salvage radiotherapy setting with and without hormonotherapy: An individual patient data analysis of randomized trials from ICECaP database.

Ejaculatory function after radiotherapy for prostate cancer: a systematic review and meta-analysis.

Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment.

Risk of Anxiety Disorders in Men With Prostate Cancer: A National Cohort Study.

Integrative identification of non-coding regulatory regions driving metastatic prostate cancer.

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.

Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer.

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study

MRI characteristics predict risk of pathological upgrade in patients with ISUP grade group 1 prostate cancer.

Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment.

Targeted Prostate Biopsy: How, When, and Why? A Systematic Review.

Effectiveness of ChatGPT 4.0 in Telemedicine-Based Management of Metastatic Prostate Carcinoma.

Comparison of PSMA immunohistochemistry scoring systems to parametric [18F]PSMA-1007 PET/MRI in primary prostate cancer.

Comparative Performance of 68Ga-PSMA-11 PET/CT and Conventional Imaging in the Primary Staging of High-Risk Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy.

Fatigue Management in Advanced Prostate Cancer: Real-World Insights From Qualitative Interviews With Patients.

Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial.

Association of Baseline Magnetic Resonance Imaging Prostate Imaging Reporting and Data System Score With Prostate Cancer Active Surveillance Early Biopsy Reclassification: Data From the Michigan Urological Surgery Improvement Collaborative (MUSIC)

Multiplex imaging of localized prostate tumors reveals altered spatial organization of AR-positive cells in the microenvironment.

Prostate cancer disparities in clinical and survival patterns among Black and Latino patients considering nativity: findings from the California Cancer Registry.

Extracellular Vesicles heterogeneity through the lens of multiomics.

Proteomic landscape profiling of primary prostate cancer reveals a 16-protein panel for prognosis prediction.

Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells.

Targeting adenocarcinoma and enzalutamide‑resistant prostate cancer using the novel anti‑androgen inhibitor ADA‑308.

PIONEER big data platform for prostate cancer: lessons for advancing future real-world evidence research.

YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer.

Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer.

Systematic review and recommendations for re-irradiation for intraprostatic radiorecurrent prostate cancer after definitive radiation therapy.

SECuRE Trial Advances: No Dose Limiting Toxicities and Strong Preliminary Efficacy Data in First Multi-Dose Cohort

Observation With or Without Subsequent Salvage Therapy for Pathologically Node-positive Prostate Cancer With Negative Conventional Imaging: Results From a Large Multicenter Cohort.

Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial.

Quantification of Gleason Pattern 4 Metrics Identifies Pathologic Progression in Patients With Grade Group 2 Prostate Cancer on Active Surveillance.

Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics.

Homologous Recombination Repair Testing Patterns and Outcomes in mCRPC by Alteration Status and Race.

Amiloride Sensitizes Prostate Cancer Cells to the Reversible Tyrosine Kinase Inhibitor Lapatinib by Modulating ERBB3 Subcellular Localization.

Oncologic Outcomes of Incidental Versus Biopsy-diagnosed Grade Group 1 Prostate Cancer: A Multi-institutional Study.

Silver Nanoparticles (AgNPs) Uptake by Caveolae-Dependent Endocytosis is Responsible for Their Selective Effect Towards Castration Resistant Prostate Cancer.

Moderately hypofractionated prostate-only versus whole-pelvis radiotherapy for high-risk prostate cancer: A retrospective real-world single-center cohort study.

Safety and feasibility of "three arms settings" robot-assisted radical prostatectomy using the Hugo RAS system: surgical set-up in a double-center large case series.

Extracapsular extension risk assessment using an artificial intelligence prostate cancer mapping algorithm

Artificial Intelligence Improves the Ability of Physicians to Identify Prostate Cancer Extent.

Study Confirms AI Outperforms Conventional Methods for Prostate Cancer Extracapsular Extension Detection, Offering More Accurate Risk Assessments for Surgical Decisions

The Impact of Radical Prostatectomy Versus Radiation Therapy on Cancer-Specific Mortality for Nonmetastatic Prostate Cancer: Analysis of an Other-Cause Mortality Matched Cohort.

Prevention of Prostate Cancer Metastasis by a CRISPR-delivering Nanoplatform for Interleukin-30 Genome Editing.

Hospital-Level Variability in the Adoption of Image-Guided Focal Therapy for Localized Prostate and Kidney Cancer.

Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial.

Testosterone recovery after androgen deprivation therapy.

Racial, Ethnic, and Socioeconomic Disparities in Rates of Stage IV Prostate Cancer After USPSTF Category "D" Recommendation Against Prostate-Specific Antigen Screening: A Retrospective Cohort Study - Beyond the Abstract

UroAlerts - Prostate Cancer Weekly

Prostate Cancer

Login